CSL Ltd. shares tumbled 11% after the Australian biotech reported an 81% plunge in first-half profit, falling short of analyst estimates. The company's interim CEO faces mounting pressure as asset write-downs, a weak vaccine market, and years of declining investor confidence converge to hammer the stock.

CSL's interim leadership transition comes at a precarious moment for the blood plasma and vaccine giant. The massive profit decline reflects both one-time charges and ongoing structural challenges in its vaccine business. Market analysts point to years of eroding investor trust as a key factor in the stock's sharp reaction.

The share price collapse underscores CSL's struggle to regain market confidence after a prolonged period of underperformance. With the new CEO inheriting these challenges, investors are watching closely to see if strategic changes can reverse the company's fortunes and restore its premium valuation in the biotech sector.